ZINTRX Trademark

Trademark Overview

On Monday, September 30, 2024, a trademark application was filed for ZINTRX with the United States Patent and Trademark Office. The USPTO has given the ZINTRX trademark a serial number of 98778695. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Friday, June 13, 2025. This trademark is owned by Zintrx, LLC. The ZINTRX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development services of new pharmaceutical products
zintrx

General Information

Serial Number98778695
Word MarkZINTRX
Filing DateMonday, September 30, 2024
Status645 - FINAL REFUSAL - MAILED
Status DateFriday, June 13, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesResearch and development services of new pharmaceutical products

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateMonday, September 30, 2024
Primary Code042
First Use Anywhere DateSunday, September 1, 2024
First Use In Commerce DateWednesday, September 11, 2024

Trademark Owner History

Party NameZintrx, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressSlidell, LA 70461

Trademark Events

Event DateEvent Description
Monday, September 30, 2024NEW APPLICATION ENTERED
Friday, April 4, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, September 30, 2024APPLICATION FILING RECEIPT MAILED
Monday, April 7, 2025ASSIGNED TO EXAMINER
Tuesday, April 8, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 8, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 8, 2025NON-FINAL ACTION WRITTEN
Tuesday, April 8, 2025NON-FINAL ACTION E-MAILED
Tuesday, April 8, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 8, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 17, 2025NON-FINAL ACTION WRITTEN
Thursday, April 17, 2025NON-FINAL ACTION E-MAILED
Thursday, April 17, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 17, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 17, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, April 17, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, May 7, 2025NON-FINAL ACTION E-MAILED
Wednesday, May 7, 2025NON-FINAL ACTION WRITTEN
Wednesday, May 7, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, May 8, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 13, 2025FINAL REFUSAL WRITTEN
Friday, June 13, 2025FINAL REFUSAL E-MAILED
Friday, June 13, 2025NOTIFICATION OF FINAL REFUSAL EMAILED
Thursday, May 8, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 8, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE

Related Keywords

zintrx products pharmaceutical services development research